Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CTX340

Gene editing · Gene editing: angiotensinogen (AGT) · developed by CRISPR Therapeutics

Phase 1/2 Most advanced trial
CRSP Developer
1 Registered trials

What is CTX340?

CTX340 is an in vivo gene editing therapy that uses CRISPR-Cas9 to target and disrupt the human angiotensinogen (AGT) gene in the liver. It is being studied in hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene editing
Targets
angiotensinogen (AGT)
Mechanism
Gene editing: angiotensinogen (AGT)
Pathways
renin-angiotensin system
Therapy area
Cardiovascular
Developer
CRISPR Therapeutics AG (CRSP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07758634 Phase 1/2 Hypertension Recruiting CRSP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypertension

Other drugs acting on AGT

More from CRISPR Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.

Follow CRSP, the company behind CTX340

See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRSP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.